glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research Medscape | The use of

Cost-effectiveness analyses of antihypertensive medicines: A systematic review

The median time elapsed from the earliest patent filing date within a given product to the expiration date of the last-to-expire patent or exclusivity on that product was 31.9 years (IQR: 29.9-36.6)

Cardiovascular side effects with semaglutide are generally mild, and the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with established heart disease

Patient-centered medicine is the best medicine, he says

Since the discovery of insulin, the main goal of diabetes treatment has been the control of glycaemia to prevent complications

GLP-1 can directly bind to the receptors on the surface of -cells in the pancreas, inhibiting the secretion of glucagon from these cells